HOME OUR DOCTORS VISITING OUR PRACTICE OUR LOCATIONS RESOURCES FOR DOCTORS CONTACT US PATIENT SIGN IN

Featured Articles by See Clearly Vision

Top 10 Questions about Corneal Cross-Linking

Top 10 Questions about Corneal Cross-Linking

Created on: Friday, November 03, 2017
Bryan Ross

Keratoconus is one of the most common corneal disorders in the U.S. today. In 2016, the FDA approved the corneal cross-linking procedure for progressive keratoconus and corneal ectasia after refractive eye surgery. Our very own Dr. Dawn Williams wrote an article in Optometry Times answering the top 10 frequently asked questions about corneal cross-linking: 

 http://optometrytimes.modernmedicine.com/optometrytimes/news/top-10-questions-about-cross-linking

 

 

Tales from Los Angeles

Tales from Los Angeles

Created on: Monday, July 10, 2017
Christina Appleman, COMT

During the first weekend in May, a very important event took place in Tinseltown. It wasn’t a movie premiere or a celebrity plugging their latest product. In fact, it was much more exciting! The annual American Society of Cataract and Refractive Surgery (ASCRS) meeting took place in Los Angeles. While there, our very own Dr. Rajesh Rajpal hosted an event on Corneal Collagen Cross-Linking.

An expert panel of doctors was assembled to discuss the science, implementation, and future of Collagen Cross-Linking. Collagen Cross-Linking is used to treat eyes with progressive keratoconus, a condition in which the normally round cornea thins and bulges outward into a cone shape. Cross-Linking can also be used in individuals who experience ectasia after refractive surgery. Ectasia occurs when the inner layers of the cornea become weak, causing the cornea to change shape, protrude forward, and distort vision.

As the Chief Medical Officer of Avedro, which has produced the only FDA approved Corneal Collagen Cross-Linking device in the United States, Dr. Rajpal hosted and moderated the Cross-Linking event co-sponsored by Avedro and the Cornea Society. It was noted during this event that since its approval approximately one year ago, there are 1,500 Cross-Linking systems in the U.S. and over 250,000 treatments have been performed. See Clearly Vision is proud to be one of the first and primary practices to conduct the clinical trials for approval of Corneal Collagen Cross-Linking. To learn more about Collagen Cross-Linking, please call 703-827-5454 to schedule an appointment today. 

To see the Los Angeles Cross-Linking symposium, CLICK HERE.

Attachments

(PNG FILE)

TrueTear™ - The New Dry Eye Therapy

TrueTear™ - The New Dry Eye Therapy

Created on: Thursday, June 01, 2017
Bryan Ross

 Do you have dry eye issues? TrueTear™ could be the product for you!

We are excited to be the first practice in Northern Virginia to offer TrueTear™ by Allergan. TrueTear™ is an intranasal neurostimulating device that helps increase tear production for those suffering with dry eyes without having to apply eye drops or artificial tears. This new innovative product is the first FDA-approved device that will help patients produce their own natural tears. Interested in learning more about TrueTear™? Give us a call at (877)234-2020
 
Additional information can be found here:

Attachments

(JPG FILE)

From Halloween to hospital? Avoid non-prescription costume contacts to save your sight! One teen’s cautionary tale, as seen on Good Morning America:

From Halloween to hospital? Avoid non-prescription costume contacts to save your sight! One teen’s cautionary tale, as seen on Good Morning America:

Created on: Friday, October 28, 2016
Bryan Ross

From Halloween to hospital? Avoid non-prescription costume contacts to save your sight! One teen’s cautionary tale, as seen on Good Morning America: http://bit.ly/1M2syhl

 

Using costume contacts to complete your Halloween look is great, as long as you have a prescription.

Using costume contacts to complete your Halloween look is great, as long as you have a prescription.

Created on: Monday, October 24, 2016
Bryan Ross

Using costume contacts to complete your Halloween look is great, as long as you have a prescription. Watch this video to learn what can happen if you don’t. http://bit.ly/1ByZhpA

 

Scratches, sores, infections…blindness. All of these can be caused by over-the-counter costume contacts.

Scratches, sores, infections…blindness. All of these can be caused by over-the-counter costume contacts.

Created on: Friday, October 07, 2016
Bryan Ross

 Scratches, sores, infections…blindness. All of these can be caused by over-the-counter costume contacts. Here’s why you need a prescription to make your eyes look like a zombie’s this Halloween: http://bit.ly/1KkMH0r

 

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus

Created on: Friday, September 30, 2016
Bryan Ross

Logo
Sept. 28, 2016 04:01 UTC

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus

Avedro Shipping Photrexa® Viscous and Photrexa® to Ophthalmologists Nationwide

WALTHAM, Mass.--(BUSINESS WIRE)-- Avedro, Inc., an ophthalmic pharmaceutical and medical device company, is now shipping Photrexa Viscous and Photrexa, the drugs used in corneal cross-linking procedures with the KXL System. On April 15, 2016, Avedro received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System used in corneal collagen cross-linking for the treatment of progressive keratoconus. Subsequently on July 15, 2016, the company received U.S. FDA approval for the products’ second indication—for the treatment of corneal ectasia following refractive surgery.

“This is an exciting time in ophthalmology,” said Reza Zadno, PhD, recently appointed CEO for Avedro. “We are proud to announce that FDA approved cross-linking treatments are now a reality, and our Photrexa drug products are now available. Clinicians have already started to treat their patients in the U.S. who are suffering from progressive keratoconus or corneal ectasia.”

Rajesh Rajpal, MD, Chief Medical Officer for Avedro and a practicing cornea specialist at See Clearly Vision Group, added, “We were thrilled to treat our first patients after FDA approval last week in my practice. Avedro shipped the Photrexa products to over 50 locations in the U.S. over the last week, with more shipping each day, and practices are now treating patients. This marks a tremendous milestone and offers new hope to patients in the U.S., to help with their vision challenges and to treat these sight-threatening diseases.”

“Avedro’s product launch has been highly anticipated by the keratoconus community as patients can now receive the only FDA-approved cross-linking treatment available in the U.S.,” said Mary Prudden, Executive Director for the National Keratoconus Foundation. “The timing is ideal as we prepare for the first World Keratoconus Day taking place on November 10th.”

Corneal collagen cross-linking with Avedro’s Photrexa Viscous, Photrexa and the KXL system is the first and only cross-linking therapy approved by the FDA. Patients should consult their ophthalmologist to determine if corneal cross-linking is right for them. Patients and families can locate an ophthalmologist performing this procedure using the “Find a Physician” tool on Avedro’s website.

What are Photrexa Viscous and Photrexa?
PHOTREXA VISCOUS and PHOTREXA are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information
In progressive keratoconus patients, the most common ocular adverse reactions were corneal opacity (haze), punctate keratitis, corneal striae, corneal epithelium defect, eye pain, reduced visual acuity, and blurred vision.

In corneal ectasia patients, the most common ocular adverse reactions were corneal opacity (haze), corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, photophobia, reduced visual acuity, and blurred vision.

Ulcerative keratitis can occur, and patients should be monitored for resolution of epithelial defects. It is not known if CXL is safe and effective in pediatric patients below the age of 14 years.

Please see full Prescribing Information by clicking here: http://avedro.com/wp-content/uploads/dlm_uploads/13597/

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

About Keratoconus
Keratoconus is a progressive thinning and distortion of the cornea. It is the most common corneal dystrophy in the US, affecting approximately one in every 2,000 Americans1or approximately 170,000 people in the US. Keratoconus causes the cornea to bulge from its normal symmetric domelike smooth optical shape, creating an abnormal curvature that changes the cornea's optics, producing blurred and distorted vision that is difficult to correct with spectacle lenses. This progressive thinning and weakening can result in significant visual loss and may lead to corneal transplants.

About Corneal Ectasia
Corneal ectasia, a non-inflammatory condition marked by progressive corneal steepening and thinning, is a rare but serious complication of vision correction procedures. The condition can begin within a week of surgery or after several years and is associated with worsening best-uncorrected visual acuity, an increase in ocular aberrations, and decreasing best-corrected distance visual acuity.

About Avedro, Inc.
Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction.

Avedro’s Photrexa Viscous, Photrexa and KXL products are approved for sale in the United States for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro’s products sold outside of the United States include capital equipment such as the UV-X devices, the KXL® and Mosaic™ Systems, and related proprietary pharmaceuticals such as the VibeX® and MedioCROSS® formulations. Avedro distributes its products in countries outside of the United States through a network of ophthalmic medical device distributors.

1 National Eye Institute (NEI). Facts About The Cornea and Corneal Disease. http://www.nei.nih.gov/health/cornealdisease/#12

 

Contacts

Avedro, Inc.
David Iannetta, 1-844-528-3376
info@avedro.com
or
Media:
BioComm Network, Inc.
Tad Heitmann, 949-494-3140
theitmann@biocommnetwork.com
or
BioComm Network, Inc.
Michele Gray, 917-449-9250
michele_gray@me.com

 

Source: Avedro, Inc.

 

FDA Approval for Collagen Cross-Linking

FDA Approval for Collagen Cross-Linking

Created on: Saturday, May 28, 2016
See Clearly Vision

See Clearly Vision is proud to announce the FDA approval for Collagen Cross-Linking for progressive Keratoconus.  Since the induction of Collagen Cross-Linking in the United States, Dr. Rajesh Rajpal, Dr. Khoa Hoang, Dr. Christine Wisecarver, Dr. Dawn Williams and the staff at See Clearly Vision conducted rigorous clinical trials and have provided their expertise to lead the way for this highly anticipated procedure. We look forward to being one of the first in the industry to provide this groundbreaking treatment to progressive Keratoconus patients. 

Please visit the link http://www.businesswire.com/news/home/20160418006610/en/ for additional information about Collagen Cross-Linking.  To see if Collagen Cross-Linking can benefit you, please feel free to call us at (703) 827-5454 to schedule an appointment for an evaluation.

Blog Home